INCANNEX HEALTHCARE INC
IXHLNASDAQTrading Snapshot
- Day Range
- $3.29 – $3.34
- 52-Week Range
- $2.49 – $19.71
- Volume
- $1.91B
- Avg Volume
- $1.55B
- Shares Outstanding
- 12.0M
- Next Earnings
- Oct 28, 2026
Fundamentals Snapshot
- Annual Revenue
- $86,000
- Last Q Revenue
- $23,947
- P/E Ratio
- —
- P/S Ratio
- 405.3x
- EPS (TTM)
- $-12.90
- Dividend Yield
- —
- Dilution (1yr)
- +98.1%
Why Investors Own IXHL
- ✓High-growth profile — revenue up +11.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 38% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INCANNEX HEALTHCARE INC
IXHL
StockOtter · stockotter.spaceAbout INCANNEX HEALTHCARE INC
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Head to Head Survey: Scilex (NASDAQ:SCLX) versus Incannex Healthcare (NASDAQ:IXHL)
Scilex (NASDAQ: SCLX - Get Free Report) and Incannex Healthcare (NASDAQ: IXHL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the str
Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position
Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040 Approxi
Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X
First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation First patient dosing r
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for h